Jefferies Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsOct 3 08:31 ET · Ratings

Buy Rating Affirmed for Rapport Therapeutics Amid Promising Phase IIa Epilepsy Study and RAP-219's Market Potential

TipRanksOct 3 08:17 ET · Ratings

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

GlobeNewswireSep 5 07:00 ET

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswireAug 29 07:00 ET

TD Cowen Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

TipRanksAug 8 14:26 ET · Ratings

Rapport Therapeutics GAAP EPS of -$1.70 Misses by $1.02

Seeking AlphaAug 8 09:33 ET